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Abstract
Antiangiogenic agents caused paradoxical increase in pro-growth and pro-angiogenic factors and 
caused tumor growth in glioblastoma (GBM). It is hypothesized that paradoxical increase in pro-
angiogenic factors would mobilize Bone Marrow Derived Cells (BMDCs) to the treated tumor and 
cause refractory tumor growth. The purposes of the studies were to determine whether whole body 
irradiation (WBIR) or a CXCR4 antagonist (AMD3100) will potentiate the effect of vatalanib (a 
VEGFR2 tyrosine kinase inhibitor) and prevent the refractory growth of GBM. Human GBM were 
grown orthotopically in three groups of rats (control, pretreated with WBIR and AMD3100) and 
randomly selected for vehicle or vatalanib treatments for 2 weeks. Then all animals underwent 
Magnetic Resonance Imaging (MRI) followed by euthanasia and histochemical analysis. Tumor 
volume and different vascular parameters (plasma volume (vp), forward transfer constant (Ktrans), 
back flow constant (kep), extravascular extracellular space volume (ve) were determined from 
MRI. In control group, vatalanib treatment increased the tumor growth significantly compared to 
that of vehicle treatment but by preventing the mobilization of BMDCs and interaction of CXCR4-
SDF-1 using WBIR and ADM3100, respectively, paradoxical growth of tumor was controlled. 
Pretreatment with WBIR or AMD3100 also decreased tumor cell migration, despite the fact that 
ADM3100 increased the accumulation of M1 and M2 macrophages in the tumors. Vatalanib also 
increased Ktrans and ve in control animals but both of the vascular parameters were decreased 
when the animals were pretreated with WBIR and AMD3100. In conclusion, depleting bone 
marrow cells or CXCR4 interaction can potentiate the effect of vatalanib.
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 INTRODUCTION
Glioblastoma (GBM) is hypervascular tumor. Clinicians are using anti-angiogenic agent in 
addition to surgery, radiotherapy and chemotherapy (Venur et al., 2015; Rovere, 2014). Both 
in clinical and preclinical cases of GBM, agents targeting Vascular Endothelial Growth 
Factor (VEGF)-VEGF Receptor (R) signaling pathways are routinely being used (Ali et al., 
2010, 2013; Batchelor et al., 2007; Ferrara et al., 2005; Gerstner et al., 2007; Reardon et al., 
2008). Our group have previously used various VEGFR Tyrosine Kinase Inhibitors (TKIs) in 
preclinical models of human GBM and the results are not encouraging (Ali et al., 2010, 
2013). Our results using vatalanib (a VEGFR2 TKI) indicated the activation of alternative 
pathways for neovascularization and release of factors/chemokines, such as stromal cell 
derived factor 1-alpha (SDF-1α), from the tumor cells that mobilize bone marrow cells and 
enhanced accumulation to the site of GBM (Ali et al., 2010). It has been observed that 
treatment with vatalanib caused increased growth (resistant to treatment) of GBM (Ali et al., 
2010). It is important to determine whether decreasing the Bone Marrow Derived Cells 
(BMDCs) or preventing the interaction of Bone Marrow Progenitor Cells (BMPCs) with 
secreted SDF-1α will attenuate the GBM resistant to vatalanib treatment.
Suppression of bone marrow (myeloablation) can be achieved by different methods such as 
using high dose of toxic chemotherapeutic drugs that suppress bone marrow or by high dose 
of whole body irradiation (Andrade et al., 2011; Barrett et al., 1975; Kishi et al., 1994; 
Smith and Boots, 1980). In both the cases, antibiotics are given to combat infection and the 
bone marrow is replenished by transplanting bone marrow or hematopoietic stem cells 
(Madonna et al., 1991). However, to decrease the circulating mononuclear cells or decrease 
the availability of BMDCs, a sub lethal whole body irradiation or lower dose of 
chemotherapeutics can be used (Andrade et al., 2011; Garg et al., 2010; Goldschmidt et al., 
1998; Kallmeyer et al., 1998; Ma et al., 2003). There has not been any report showing that 
the relation of lower number of available BMDCs and the effect of vatalanib in GBM.
Most of the BMPCs have CXC chemokine receptor 4 (CXCR4) and the receptor is specific 
for SDF-1α. The SDF-1α is upregulated in hypoxic tumors. The SDF-1α is a chemokine 
that is expressed in tumor cells and released in the circulation following hypoxia in the 
tumor (with the up-regulation of HIF-1α) (Arbab et al., 2008; Ceradini et al., 2004; Moore et 
al., 2001). In an experiment, Heissig et al. (2002) determined the mechanisms of releasing 
Hematopoietic Stem Cells (HSCs) and EPCs from bone marrow. Because of upregulation 
and secretion of SDF-1α in GBM due to presence of hypoxia, there will be more 
mobilization of BMPCs and accumulation of different progenitor cells in GBM causing 
increased immunosuppression, neovascularization and tumor growth. Our previous reports 
indicated that vatalanib treatment increased hypoxia in GBM and upregulation of SDF-1α 
causing resistant to vatalanib treatment and increased growth of GBM (Ali et al., 2010). 
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Therefore, it is hypothesized that by using CXCR4 antagonist (ADM3100) the interaction of 
CXCR4 with accumulated BMPCs in the GBM can be prevented and would decrease tumor 
growth following vatalanib treatment.
Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) has been used in the 
assessment of GBM growth and different vascular parameters following treatments (Bagher-
Ebadian et al., 2012; Chwang et al., 2014). Our group have previously used MRI technique 
to determine different vascular parameters in GBM with or without anti-angiogenic 
treatments (AAT) (Ali et al., 2010, 2013). The purpose of the study was to determine the 
effects of bone marrow manipulation either through whole body irradiation or CXCR4 
antagonist treatment on the tumor growth and vascular parameters determined by MRI with 
or without the treatment of vatalanib.
 MATERIALS AND METHODS
All animal experiments were approved by intuitional animal care and use committee and 
institutional review board of Georgia Regents University. All efforts were made to decrease 
sufferings of animals. The CO2 with secondary method was used to euthanize animals for 
tissue collection.
 Drugs, chemical and antibodies
Vatalanib was purchased from LC laboratories, Woburn, MA, USA. AMD3100 was 
purchased from TORCIS bioscience, Minneapolis, MN, USA. All buffers are from Fisher 
Scientific, USA. All antibodies are from Abcam, Cambridge, MA, USA.
 Animal groups
There were three groups of animals undergoing different treatments. (1) Control group: non-
irradiated and non-treated with AMD3100. (2) Myeloablation group; all animals in this 
group underwent whole body irradiation of 6Gy dose. Whole body irradiation was given 
using a Cs137 source 14 days before the implantation of tumor. All animals were treated 
with antibiotic for 4 weeks from the day of whole body irradiation. Following irradiation 
population of different BMDCs (CD45+, CD90+ and OX82+ cells) in peripheral blood was 
determined in randomly selected animals up to day 28. The CD90 is hematopoietic stem cell 
marker and OX82 is myeloid lineage marker for rat. (3) AMD3100 treated groups: All 
animals of this group were treated with AMD3100 (10 mg kg−1 day−1 continuously by an 
osmotic pump) from the day of tumor implantation. Randomly selected animals from each 
group were treated either with vehicle or with vatalanib from day 8 of tumor implantation 
and continued for two weeks.
 Animal model
Forty three nude rats (RNU nu/nu) 6–8 weeks of age and 150–170 g of weight (Charles 
River Laboratory, Inc. Frederick, MD) were included in the study. Orthotopic GBM was 
created by injecting 4×105 human glioma U251 cells suspended in 5 μL of saline at 3 mm to 
the right and 1 mm anterior to the bregma as described in our previous publications (Ali et 
al., 2010; Janic and Arbab, 2012; Kumar et al., 2012). In brief, animals were anesthetized 
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with 100 mg kg−1 ketamine and 15 mg kg−1 xylazine i.p. The surgical zone was swabbed 
with betadine solution, the eyes coated with Lacri-lube and the animals were immobilized in 
a small animal stereotactic device (Kopf, Cayunga, CA). After draping, 1 cm incision was 
made 2 mm to the right of the midline 1 mm retro-orbitally, the skull exposed with cotton-tip 
applicators and a 23G needle tip was used to drill a hole 2 mm to the right of the bregma, 
taking care not to penetrate the dura. A #2701 10 μL Hamilton syringe with a #4 point, 26s 
gauge-needle containing tumor cells (4×105) in 5 μL was lowered to a depth of 5 mm, then 
raised to a depth of 4 mm. The tumor cells were injected stepwise at a rate of 0.5 μL/30 sec 
until the entire volume was injected. During and after the injection, careful note was made of 
any reflux from the injection site. After completing the injection, we waited 2–3 min before 
withdrawing in a stepwise manner. The surgical hole was sealed with bone wax. Finally, the 
skull was swabbed with betadine before suturing the skin over the injection site.
 Treatment schedules
Animals from control group were randomly assigned to either the drug treatment (vatalanib, 
n = 8) or the vehicle (n = 6). Animals from myeloablation group were randomly assigned to 
either the drug treatment (vatalanib, n = 9) or the vehicle (n = 8). Animals from AMD3100 
treated group were randomly assigned to either the drug treatment (vatalanib, n = 6) or the 
vehicle (n = 6). Vatalanib (LC laboratories, Woburn, MA, USA) was prepared for oral 
administration using the vehicle (cremophor-EL: DMSO: PBS at 1:1:8) and was 
administered orally by gavage, once a day at a dose of 50 mg kg−1 per feeding for two weeks 
starting on day 8 following implantation of orthotopic GBM. Vehicle treated animals 
received vehicle (cremophor-EL: DMSO: PBS at 1:1:8) by oral gavage for two weeks 
starting on day 8 following implantation of tumor. Drug or vehicle administration started 
eight days after tumor implantation and continued for two weeks (5 days/week). On day 22 
following tumor implantation, animals underwent in-vivo MRI followed by euthanasia and 
collection of brain tissue.
 In vivo MR imaging
Animals were anesthetized with 2% isoflurane, steadily supplied with oxygen while secured 
to a customized cradle. All studies were performed in a horizontal 7 Tesla BioSpec MRI 
spectrometer (Brucker Instruments, Bellerica, MA) equipped with a 12 cm self-shielded 
gradient set (45 gauss/cm max). The radio frequency (rf) pulses were applied using a 
standard transmit/receive (Tx/Rx) volume coil (72 mm I.d.), actively decoupled from the 
two-channel Bruker quadrature receive coil positioned over the center line of the animal 
skull. Stereotaxic ear bars were used to minimize movement during the imaging procedure. 
Rat temperature was maintained at 37.4°C using a recirculating water bath. All MRI image 
sets were acquired with a 32×32 mm2 Field Of View (FOV). Animals were first located with 
the tumor center corresponding to the magnet center by a tri-planar Fast Low Angle Shot 
(FLASH) sequence. Subsequent scans acquired using T1-weighted (pre- and post-contrast), 
T2-weighted, spoiled gradient recalled (SPGR) echo with a variable flip angle and SPGR 
DCE-MRI scans to estimate Ktrans, kep, vp and ve. Pre- and -post contrast T1-weighted 
images were acquired in a spin-echo T1-weighted multi-slice sequence (TR/TE = 800/9 ms, 
256×256 matrix, 10 slices (1.5 mm thick), number of summed acquisitions (NEX) = 4). 
Spin-echo T2 weighted images were obtained using standard two Dimensional Fourier 
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transformation (2DFT) multi-slice (10 slices, 1.5 mm thickness) multi-echo sequence: 
TE/TR = 12, 24, 36, 48, 60, 72/3000, 256×256 matrix and NEX = 1. Prior to the DCE-MRI 
sequence, multi Flip Angle (FA) SPGR sequence was employed allowing a voxel-by-voxel 
estimation of T1 in the tissue pre Contrast Agent (CA) administration. Multi FA SPGR 
sequence parameters are as follows: Flip angles = 3, 5, 7, 12, 15, 25, 45 and 70°, matrix 
128×128, ten 1.5 mm slices, TE/TR=3/100 ms. The DCE-MRI sequence was SPGRE 
sequence with the same geometry and timing but with a fixed flip angle of 35°, an 
acquisition of 90 image sets at 6 sec time intervals for a total run time of about 9 min. At 
image 6–7 of the SPGR sequence a bolus injection of the CA (Magnevist, Bayer Healthcare 
Pharmaceuticals, Wayne, New Jersey), 0.25 mmol kg−1 at undiluted concentration, no flush, 
was performed by hand push, followed by a slight draw back.
 Pharmacokinetic analysis
Dynamic contrast-enhanced MR imaging was performed using a transverse T1W SPGR 
acquisition that consisted of obtaining pre-contrast (6–7 sequences) and dynamic post 
contrast images up to 9 min after the contrast injection. Dynamic contrast-enhanced MR 
images followed by extended Tofts model were used to estimate the transfer constants Ktrans 
and kep, plasma volume of tumor blood volume (vp) and interstitial space volume (ve) 
according to previous methods (Bagher-Ebadian et al., 2012; Ewing et al., 2006).
The Ktrans is the unidirectional transfer rate constant of the contrast from plasma across the 
vascular endothelium and Blood Brain Barrier (BBB) into the interstitial fluid. The kep is the 
reverse transfer rate constant from the extravascular compartment to the vascular 
compartment. The vp is the fractional volume of the contrast agent vascular distribution 
space, usually thought to be the plasma distribution space. If the trans-vascular transfer of 
the contrast agent is passive, the two rate constants are related via the interstitial space 
volume fraction: ve = Ktrans/kep. Our recent publication shows the validity of this method 
(Bagher-Ebadian et al., 2012). The Ktrans, kep, vp and ve of the tumors (both treated and 
control) were determined by drawing irregular Regions Of Interests (ROIs) encompassing 
the whole tumor. An investigator blinded to both treated and untreated animals drew the 
ROIs and determined the values.
 Measurement of tumor volume
Post contrast T1-weighted images were used to determine the volume of the tumor in each 
animal. Two investigators blinded to the treatment groups determined the volume by 
drawing irregular ROIs around the tumor and multiplying the area with the slice thickness.
 Histopathology
Animals used for the histology analysis were euthanized, perfused by intra-cardiac injection 
of 100 mL PBS, followed by 3% paraformaldehyde. Brains were collected and fixed in 3% 
paraformaldehyde containing 3% sucrose. Tissue sections were prepared from either frozen 
or paraffin preparations. Standard histochemical staining procedures were performed as 
recommended by the suppliers of primary antibodies. Our histochemical analysis 
concentrated on the markers of neovascularization, human specific cells and, marker of 
CD86 and CD163. Sections were stained to determine neovascularization by using von-
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Willebrand factor (vWF, Dako, USA), invasion of tumor cells by targeting human specific 
major histocompatibility complex-1 (MHC-1). To determine whether whole body irradiation 
can decrease or AMD3100 increase the migration of mononuclear cells (especially the 
macrophage population) in the tumors, Presence of M1 or M2 macrophage populations was 
determined by staining with either CD86 (for M1) or CD163 (for M2) antibodies, 
respectively.
 Evaluation of micro-vessel density (MVD)
Micro-vessels were detected by immunohistochemical staining with vWF, which is well 
established for determining neovascularization in different lesions (Arbab et al., 2012; 
Christensen et al., 2010; Zhang et al., 2011). All images were visually compared to see the 
distribution patterns and vWF positive areas at the central and peripheral parts of the tumors. 
Each cell positive for vWF was considered to be a neo-vessel. Five “Hot spots” [area with 
highest vessel concentration] from each slide were identified, photomicrographed and vWF 
positive areas were measured by color thresholding method using ImageJ program. The total 
area of histology section viewed on microphotography was noted and MVD was calculated 
as previously described (Weidner et al., 1991). The vWF area was expressed as % total area 
of photomicrographs.
 Tumor cell migration and invasion
The distance between the MHC-1 positive cells and the margin of the main tumor mass was 
evaluated using low, 4–10× image magnification. The tumor periphery was confirmed on 
high magnification before all measurements. An irregular line was drawn at the most 
peripheral part of the tumor that showed continuation to the primary tumor mass. Any 
MHC-1 positive cells away from the drawn line were considered invasive cells away from 
the primary tumor mass. A perpendicular line was drawn from the invasive tumor cells or 
tumor foci (center of the foci) to the drawn line at the tumor periphery and the distance was 
noted. Distance from migrated individual cell or distal tumor foci to the periphery of the 
primary tumor mass were determined and the average values were calculated. The analysis 
was done using the software supplied by the vendor (Troup View Software, Irvine, CA). The 
average distance between the MHC-1 positive cells and the tumor margin was determined 
for vatalanib and vehicle treated animals in each groups. The analysis was done according to 
our published method (Ali et al., 2013).
 M1 and M2 cells
To determine the BMDCs as well as tumor associated macrophages, CD45 and CD68 
staining were performed. Sections were also stained for the presence of M1 (CD86) and M2 
(CD163) macrophages. Five “Hot spots” [area with highest positive cells] from each slide 
were identified; photomicrographed.
 Statistical analysis
Comparison between drug and vehicle treated groups was done by using one way ANOVA 
with PLSD Post hoc test. All data are expressed as Mean±Standard Error of Mean (SEM) 
unless otherwise stated. Any p-value of <0.05 was considered statistically significant.
Shaaban et al. Page 6
Int J Cancer Res. Author manuscript; available in PMC 2016 July 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
 RESULTS
 Myeloablation
Figure 1 shows decrease of CD45+, hematopoietic stem cells (CD90 for rat) and myeloid 
lineage (OX-82 for rat) in the peripheral blood of rats by day 14 that received whole body 
irradiation. It was expected that by reducing BMDCs to be released in the peripheral blood, 
there will be less bone marrow cells migrated to the tumor following AAT (vatalanib 
treatment) and the tumor growth will be inhibited following vatalanib administration. All 
nine animals were followed for five different days (days 0, 2, 7, 14 and 21) and longitudinal 
data from each animal are show separately. Animals underwent whole body irradiation of 
6Gy and followed until day 21. During follow up peripheral blood (PBMC) was collected 
just before irradiation and on days 2 (D2), 7 (D7), 14 (D14) and 21 (D21). Most of the cell 
types went down significant on day 14. Each graph represents one time point from one 
sample. To show the similarity in each animal the data were not combined (Fig. 1).
 Tumor volume
Tumor volume measurement from post contrast T1WI MR Images showed significantly 
(p<0.01) increased tumor growth in control group of animals following the treatment of 
vatalanib (Fig. 2a). The previous publications explained the increased growth following 
vatalanib treatment due to activation of alterative pathways of neovascularization and, 
mobilization and accumulation of BMDCs in the glioma (Ali et al., 2010, 2013). Based on 
the findings it was hypothesized that decreasing the availability of BMDCs and preventing 
the interaction of BMDCs to SDF-1α would prevent the detrimental effect of vatalanib. 
Results from the tumor volume measurements proved our hypothesis that decreasing the 
availability of BMDCs in the peripheral blood (Fig. 1) using whole body sub-lethal 
irradiation prevented the tumor growth following the use of vatalanib in the irradiated 
animals compared to the corresponding vehicle treated animals (Fig. 2a and b). In control 
group of animal vatalanib treatment increased the tumor growth significantly compared to 
that of vehicle treatment (vehicle 123.41±22.26 mm3 vs vatalanib 331.24±64.93 mm3) but 
by preventing the mobilization of BMDCs using WBIR (170.72±56.19 vs 152.80±34.57 
mm3) paradoxical growth of tumor was controlled. However, there was no change in the 
tumor volume in vehicle treated animals (whole body irradiation plus vehicle) between 
control and irradiated groups (123.41±22.26 vs 170.72±56.19 mm3) (Fig. 2a and b). 
Similarly, when the interaction of BMDCs with tumor cell secreted SDF-1α using 
AMD3100 (CXCR4 antagonist) was blocked; it prevented the tumor growth following the 
use of vatalanib compared to the corresponding vehicle treated animals (165.91±32.73 vs 
169.49±15.33 mm3). However, AMD3100 itself (AMD3100 plus vehicle) could not 
decrease the tumor growth when compared with vehicle treated animals in control groups 
(123.41±22.26 vs 165.91±32.73 mm3) (Fig. 2a and b).
 Vascular parameters
Measurement of different vascular parameters derived from DCE MRI showed the status of 
tumor vascularity, vascular permeability and extravascular extra cellular space volume 
following vatalanib treatment in different pre-conditioned groups of animals (control, 
irradiated and AMD3100). In control group of animals, vatalanib treated caused borderline 
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significant increase in vascular permeability (forward transfer constant, Ktrans) compared to 
the corresponding vehicle treated animals (0.013±.003 vs 0.019±.003 sec−1). Vatalanib 
treatment also significantly increased the extravascular extracellular space (ve) in control 
group of animals (0.027±.006 vs 0.053±.011 mg min−1). These effects were changed when 
the animals were pre-conditioned with whole body irradiation or administration of 
AMD3100 before the use of vatalanib (Fig. 3). Figure 3 shows that WB irradiation and 
AMD3100 pretreatment normalized permeability and Ve to that of vehicle treated animals. 
Data are expressed in Mean±SEM.
 Tumor neovascularization
Status of neovascularization following treatments in different groups of animals was 
assessed by histochemical staining of vWF (neovessels). There was no difference in the 
distribution of neovascularization and vWF positive areas in control group between vehicle 
and vatalanib treated animals (4.82±0.9 vs 3.11±0.29%). In both WBIR and AMD3100 
groups, vatalanib treated animals showed increased vWF positive areas compared to 
corresponding vehicle treated animals (WBIR: 6.60±2.36 vs 12.46±5.45%, AMD3100: 
10.43±1.03 vs 16.65±0.61%). However, significant difference was observed only in 
AMD3100 group (p<0.01). When compared the vehicle treated animals, only AMD3100 
group showed significantly higher percent of vWF positive areas (p<0.01) compared to that 
of control. Following vatalanib treatment both WBIR and AMD3100 groups showed 
significantly higher vWF positive areas (p<0.05) compared to that of control group. Both 
whole body irradiation and AMD3100 treated animals showed well defined vascularization 
in the tumors, especially at the peripheral part (Fig. 4).
 Invasion of tumor cells
Human U-251 cells were implanted in nude rats. To determine human cells in rats, MHC-1 
or HLA-A marker was used, which is specific for human cells. MHC-1 positive cells will 
indicate the human cells in rat brain. Measurement of the distance traveled by the MHC-1 
positive cells from the periphery of the primary tumor mass will indicate the invasion or 
migration of U-251 cells following different treatments. As shown in our previously study 
vatalanib treatment in control group of animals decreased the cell migration significantly 
(vehicle 284.15±18.58 μm vs vatalanib 223.48±13.80 μm) (Ali et al., 2013). On the other 
hand AMD3100 treated group of animals showed significantly increased migration of cells 
following administration of vatalanib (vehicle 165.25±9.38 μm vs vatalanib 235.75±20.44 
μm) (Fig. 5, arrows). Neither vehicle nor vatalanib treated animals in whole body irradiated 
group of animals showed increased migration of cells (vehicle 205.26±19.02 μm vs 
vatalanib 223.28±17.84 μm). Data are expressed in Mean±SEM.
 Tumor associated macrophages
Due to manipulation of bone marrow cells (myeloablation to decrease and AMD3100 to 
mobilize) it was expected differential accumulation of BMDCs cells in the tumor. It was also 
expected difference in the number of tumor associated macrophages and the population of 
MI (CD86) vs M2 (CD163). These markers have been used to differentiate two populations 
(David et al., 2015; Mellins et al., 2011). As expected pre-treatment with AMD3100 
increased the accumulation of both M1 and M2 populations in the tumors both in vehicle 
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and vatalanib treated groups (Fig. 6). Vatalanib treatment showed robust accumulation of 
M1 cells in the tumor compared to that of corresponding vehicle treated group (brown cells). 
Both the control and whole body irradiated groups did not show increased accumulation of 
either M1 or M2 cells following vatalanib treatment.
 DISCUSSION
Due to hypervascular nature of GBM, antiangiogenic agents targeting VEGF-VEGFR 
pathways have been used as first line of treatment or as adjuvants along with chemotherapy 
and radiotherapy (Gerstner et al., 2011; Los et al., 2007; Reardon et al., 2009; Venur et al., 
2015). However, both clinical and pre-clinical studies indicated varying degree of successes 
with progression of tumor on extended use (Ali et al., 2010, 2013; Bergers and Hanahan, 
2008; Norden et al., 2008; Paez-Ribes et al., 2009). Explanation for the failure of these 
antiangiogenic agents is that AAT caused marked hypoxia due destruction of blood vessels 
followed by activation of alterative pathways of neovascularization and enhance 
mobilization of BMPCs. Similar phenomenon was also noticed in previous pre-clinical 
model, where vatalanib was used and causing activation of alternative pathways of 
neovascularization and enhanced both angiogenesis and vasculogenesis in a rat model of 
human GBM (Ali et al., 2010, 2013). Moreover, our chimeric mice model showed increased 
accumulation of bone marrow derived cells in the GBM treated with vatalanib (Achyut et al., 
2015). Similar to previous findings and reports, current study also indicated GBM resistant 
to vatalanib treatment (in control group) causing increased tumor volume compared to that 
of vehicle treated GBM (Ali et al., 2010, 2013). Based on the previous findings and the 
above discussion, it can be interpreted that GBM resistant to vatalanib treatment might be 
due to activation of alternative pathways of neovascularization and mobilization of BMDCs 
to the sites of tumor. Further experiments in this study using whole body radiation to 
decrease the available BMDCs and using CXCR4 antagonist to prevent the interaction 
between BMDCs and SDF-1α also proved that BMDCs might be responsible for the GBM 
resistance to vatalanib treatment in control groups. When whole body irradiation or 
AMD3100 was used prior to vatalanib treatment, there was no increase in the tumor growth 
compared to that of corresponding vehicle treated animals. Whole body irradiation to control 
tumor growth is not a new idea but investigator was not aware of the activation of alternative 
pathways of neovascularization and mobilization of BMDCs to tumor following 
antiangiogenic treatments. Our data showed decreased level of BMDCs in the peripheral 
blood on day 14 following whole body irradiation, which might cause unavailable BMDCs 
to accumulate in the tumor following vatalanib and prevented resistance to the treatment 
(tumor growth). On the other hands, Kioi et al. (2010) has proposed low dose of CXCR4 
antagonist would prevent the interaction of BMDCs (CXCR4+cells) and SDF-1α at the 
tumor sites and prevent formation of neovascularization and tumor growth. Similar to our 
previous report, current study also did not show increased tumor growth following 
AMD3100 treatment (vehicle treated animal in AMD3100 group) even after adding 
vatalanib (Ali et al., 2013). Therefore, preventing the interaction of CXCR4 and SDF-1α 
may be an effective way of interfering neovascularization (especially vasculogenesis), 
although our published data indicated increased accumulation of BMDCs in the tumor 
following AMD3100 treatment (Achyut et al., 2015) and there were increased vWF positive 
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areas in tumors treated with vatalanib both in WBIR and ADM3100 groups in the current 
studies.
Vascular parametric analysis based on in vivo imaging such as MRI or CT is being used in 
preclinical and clinical practices, especially for GBM. With the three compartmental model, 
as done in our study, tumor blood volume (or plasma volume, Vp), forward transfer constant 
(or forward permeability, Ktrans), backward transfer constant (or backflow, Kb) and 
extravascular extracellular space volume (Ve) can be determined with confidence (Aryal et 
al., 2014; Bagher-Ebadian et al., 2012; Chwang et al., 2014; Ewing and Bagher-Ebadian, 
2013). Tumor may show increased blood volume if there is slow flow or increased blood 
pool. The Ktrans indicates permeability, which is also indicative of neovascularization and is 
seen in hypervascular tumors such as GBM or breast cancer (Ewing and Bagher-Ebadian, 
2013; Li et al., 2015a, b). High Ktrans is seen mostly at invasive margin of the tumors where 
most of the neovascularization is observed. Similar to Ktrans, increased kep is also seen at the 
invasive front of the tumors. The kep is dependent on the extravascular extracellular space as 
well as oncotic pressure. However, in case there is more protein in extravascular 
extracellular space, kep will be reduced and ve will be increased (McDonald and Levick, 
1993). Similar to our previously published reports, vatalanib treated animals in control group 
showed borderline significantly increased Ktrans (p = 0.07, NS) and significantly increased 
ve compared to that of corresponding vehicle treated animals (Ali et al., 2013). As shown in 
our previous as well as in current studies, vatalanib caused increased vascularization at the 
invasive margin of the GBM in control animals. Interesting findings in the current studies 
are that whole body irradiation or treatment with AMD3100 created well-defined 
vascularization even after vatalanib treatment, which could be the reason for not increasing 
the transfer constants such as Ktrans, kep and ve.
Tumor microenvironment could be one of the major determinants for tumor invasion and 
change of phenotypes (Tredan et al., 2015; Vitale et al., 2014; Weiss et al., 2014; Xu et al., 
2014). Our recent publication showed the phenotypical changes of the accumulated BMDCs 
in the tumors and there were changes in the phenotypes of the tumor cells (Achyut et al., 
2015). In this study, one of the purposes is to determine whether BMDCs has any effect on 
the tumor cell migration or whether M1 or M2 population could be related to the increase 
tumor cells migration. As expected based on our previous publications, vatalanib did not 
increase cell migration in control and whole body irradiated groups. On the other hand, 
AMD3100 treated animals showed increased accumulation of M1 and M2 population in the 
tumor and there was increased cell migration following vatalanib treatment compared to that 
of corresponding vehicle treated animals. Exact mechanisms of increased cell migration and 
relation with M1 or M2 population is beyond the scope of this study, however, our 
unpublished data from chimeric animals showed influence of myeloid cells on the 
phenotypes of tumors (EMT), which could make tumor cells more motile and invasive, 
which is also supported by other investigators (Bae et al., 2015; Mego et al., 2015; Wu et al., 
2015).
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 CONCLUSION
In conclusion, our study investigated that BMDCs are responsible for causing drug 
resistance to vatalanib treatment in rat model of glioma. Blocking the interaction of CXCR4 
positive BMDCs with SDF-1 in tumor or depleting bone marrow cells can attenuate the 
detrimental effect of vatalanib. The MRI and vascular parametric analysis predicted the 
effects of vatalanib and showed improvement of permeability following AMD3100 or whole 
body irradiation therapies.
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Fig. 1. 
(a–c): Depletion of bone marrow derived cells by whole body irradiation. Distribution of 
different cells types, (a) Common leukocytes (CD45), (b) Rat hematopoietic stem cells 
(CD90) and (c) Myeloid lineage (OX82) in PBMC was assessed using flow cytometer
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Fig. 2. 
(a–b): Representative MR Images and tumor volume. All animals underwent MR imaging at 
the end of the studies. Representative MR Images, (a) From control, Whole Body irradiated 
(WB irrad) and CXCR4 antagonist (AMD3100) pretreated animals show changes following 
administration of vatalanib and (b) Vatalanib treatment in control animals significantly 
increased tumor volume* = p<0.05
Shaaban et al. Page 16
Int J Cancer Res. Author manuscript; available in PMC 2016 July 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. 
(a–e): Representative vascular parametric images from vehicle and vatalanib treated animals 
in control group and quantitative analysis. All animals underwent MR imaging at the end of 
the studies, (a) Representative vascular parametric images from vehicle and vatalanib treated 
animals in control group show relative changes in the permeabilities (Ktrans and kep) and 
extravascular extracellular space volume (ve). Note the increase permeabilities at the 
periphery of the tumor following vatalanib treatments. Quantitative analysis shows no 
significant differences in (b) Vp, (c) kep, (d) Borderline significant (p = 0.07) increased and 
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(e) Ktrans and significantly (*p<0.05) increased ve in vatalanib treated animals in control 
group
Shaaban et al. Page 18
Int J Cancer Res. Author manuscript; available in PMC 2016 July 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. 
Neovascularization depicted by vWF staining
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Fig. 5. 
(a–b): Representative IHC images and quantitative analysis showing tumor cell migration, 
(a) MHC-1 marker was stained to determine the human cells in rat brain, measurement of 
the distance traveled by the MHC-1 positive cells from the periphery of the primary tumor 
mass indicates the invasion or migration of U-251 cells following different treatments and 
(b) Quantitative analysis of the migration of tumor cells
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Fig. 6. 
(a–b): Representative IHC images showing accumulation of M1 and M2 macrophage 
populations in tumor. At the end of the studies brains with tumors were collected, fixed and 
paraffin sections were made for immunohistochemical analysis, (a) CD 86 and (b) CD163 
markers were stained to determine the M1 and M2 macrophage populations, respectively
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